Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.32 |
| ▸ | INMT | O95050 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12411694 | 0.77 | POLB (0.38) | POLB | |
| SCHEMBL19918741 | 0.73 | FAAH (0.36) | — | |
| SCHEMBL1155846 | 0.70 | — | — | |
| SCHEMBL23583270 | 0.69 | — | — | |
| SCHEMBL610179 | 0.69 | — | — | |
| SCHEMBL10129310 | 0.68 | INMT (0.36) | POLBINMT | |
| SCHEMBL13502696 | 0.67 | — | — | |
| SCHEMBL11557844 | 0.65 | INMT (0.35) | INMT | |
| SCHEMBL1349838 | 0.65 | — | — | |
| SCHEMBL10715121 | 0.65 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11076594-B2 | Pyrazolone compound or salt thereof, preparation method therefor, herbicide composition and use thereof | QINGDAO KINGAGROOT CHEMICAL COMPOUNDS CO., LTD. (CN) | 2021-08-03 | — | — | US | disclosed |
| US-11046684-B2 | Compound for selectively inhibiting kinase and use thereof | SHANGHAI ZHEYE BIOTECHNOLOGY LIMITED LIABILITY COMPANY (CN) | 2021-06-29 | — | — | US | disclosed |
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-9975893-B2 | Pyrazolo[3,4-c]pyridine derivatives | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2018-05-22 | — | — | US | disclosed |
| US-20180055054-A1 | PYRAZOLONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, HERBICIDE COMPOSITION AND USE THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUNDS CO., LTD. (CN) | 2018-03-01 | — | — | US | disclosed |
| US-20180055054-A1 | PYRAZOLONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, HERBICIDE COMPOSITION AND USE THEREOF | QINGDAO KINGAGROOT CHEMICAL COMPOUNDS CO., LTD. (CN) | 2018-03-01 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | CSPC ZHONGQI PHARMACEUTICAL TECHNOLOGY (SHIJIAZHUANG) CO., LTD. (CN) | 2017-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170291896-A1 | PYRAZOLO[3,4-C]PYRIDINE DERIVATIVES | F11, TFPI, F2 | POLB 2890/4885INMT 4039/4885 |
| US-20180055054-A1 | PYRAZOLONE COMPOUND OR SALT THEREOF, PREPARATION METHOD THEREFOR, HERBICIDE COMPOSITION AND USE THEREOF | THEM6, NOTUM, CYP4F11 | POLB 4417/4885INMT 1120/4885 |
| US-11076594-B2 | Pyrazolone compound or salt thereof, preparation method therefor, herbicide composition and use thereof | THEM6, NOTUM, CYP4F11 | POLB 4417/4885INMT 1120/4885 |
| US-11046684-B2 | Compound for selectively inhibiting kinase and use thereof | FGFR4, FGFR1, FGFR3 | POLB 4603/4885INMT 1790/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.